Ramco Systems selected for ERP project by Erickson
Shares of Ramco Systems traded 3% higher following the news that Erickson Incorporated has selected the company to implement its Aviation M&E MRO Solution V5.8.
Erickson advanced enterprise solutions integration will link all Maintenance, Supply Chain Management, Safety & Quality, Flight Operations, MRO Sales, and Manufacturing functions into a single system.
Modules will include EFB (electronic flight bag), Mobility, Optimization Solution, Hubs, Dashboards and Chatbot.
JSW Energy's planned acquisition of Jindal Steel plant terminated
Shares of JSW Energy rose 3% in today trade after the company aborted its plan to acquire the 1000MW (4x250 MW) thermal power plant located at Village Tamnar, District Raigarh in the state of Chhattisgarh from Jindal Steel and Power Limited.
Further, vide letter dated 28th June 2018, we had informed you that as the conditions precedent were yet to be completed, it was decided to extend the Long Stop Date from June 30, 2018, to June 30, 2019," the company said.
Strides Pharma receives USFDA warning letter for Puducherry unit
Shares of Strides Pharma fell over 4.5% in afternoon trade on Tuesday after the USFDA issued a warning letter to its Puducherry facility.
USFDA classifies Strides Puducherry facility as Official Action Indicated (OAI), we wish to inform you that the Company has now received a warning letter from USFDA relating to Puducherry facility, the company said in the filing.
The Puducherry site currently produces 6 ANDAs which will not get impacted by the recent development. However, the 10 ANDAs pending approval from the site will get deferred till the site is reclassified, the company said.
Alembic Pharma receives USFDA nod for Febuxostat tablets
Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Febuxostat Tablets, 40 mg and 80 mg. The approved ANDA is therapeutically equivalent to the: reference listed drug (RLD), Uloric Tablets, 40 mg and 80 mg, of Takeda Pharmaceuticals USA., Inc. (Takeda).
Febuxostat Tablets are xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.
HCL Tech completes acquisition of select IBM products
HCL Technologies on July 1 announced the completion of the planned acquisition of select IBM products for security, marketing, commerce, and digital solutions.
Last December, HCL Technologies had announced that it would acquire select IBM software products for $1.8bn (Rs12, 700cr) in an all-cash deal.
"As part of the deal's close, HCL takes full ownership of the research and development, sales, marketing, delivery, and support for AppScan, BigFix, Commerce, Connections, Digital Experience (Portal and Content Manager), Notes Domino, and Unica," HCL said in a statement to the exchanges.
Financial
Advisory Company in Indore, Stock
Advisory Company in Indore, Equity Tips, FreeTrading Tips , MCX Tips, sebi registered advisory company, Intraday
stock tips, Free
commodity tips
0 comments:
Post a Comment